Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Clicks: 262
ID: 270460
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
AbbVie.
Reference Key
x2017theglecaprevir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Forns X;Lee SS;Valdes J;Lens S;Ghalib R;Aguilar H;Felizarta F;Hassanein T;Hinrichsen H;Rincon D;Morillas R;Zeuzem S;Horsmans Y;Nelson DR;Yu Y;Krishnan P;Lin CW;Kort JJ;Mensa FJ;;
Journal The Lancet. Infectious Diseases
Year 2017
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/28818546
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult female male aged middle aged 80 and over Clinical Trial Phase III Multicenter Study Genotype drug therapy combination liver cirrhosis / complications* antiviral agents / administration & dosage antiviral agents / therapeutic use quinoxalines / administration & dosage hepacivirus / genetics* hepacivirus / classification hepatitis c / drug therapy* Quinoxalines / therapeutic use* sulfonamides / therapeutic use* federico j mensa sulfonamides / administration & dosage benzimidazoles / therapeutic use* hepatitis c / virology* pmid:28818546 doi:10.1016/s1473-3099(17)30496-6 xavier forns samuel s lee benzimidazoles / administration & dosage

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.